ReviewCancers2019
Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bone metastases in lung carcinoids: current challenges in diagnosis and treatment -A systematic review of an unexplored issue.Endocrine · 2026Pooled it
- Beyond Tumor Control in Sporadic Neuroendocrine Tumor: Metabolic and Bone Health During Treatment with Somatostatin Analogs.Journal of clinical medicine · 2026Article
- Ten-Year Disease Control of Metastatic Pancreatic Neuroendocrine Tumour Treated With Everolimus.Cureus · 2026Article
- Recommendations for bone-directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting.Internal medicine journal · 2026Article
- Ablative Techniques for the Management of Osseous Spine Metastases: A Narrative Review.Journal of clinical medicine · 2025Review
- Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention.Frontiers in endocrinology · 2025Review
- A Review on Bone Tumor Management: Cutting-Edge Strategies in Bone Grafting, Bone Graft Substitute, and Growth Factors for Defect Reconstruction.Orthopedic research and reviews · 2025Review
- Role of Bone Metastases in Lung Neuroendocrine Neoplasms: Clinical Presentation, Treatment and Impact on Prognosis.International journal of molecular sciences · 2024Article
- Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers.Journal of clinical medicine · 2024Review
- Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.Advances in therapy · 2024Review
- Hypercalcemia and Bone Metastasis in a Case of Large Cell Neuroendocrine Carcinoma With Unknown Primary.Case reports in oncological medicine · 2024Article
- Correctly identifying the cells of origin is essential for tailoring treatment and understanding the emergence of cancer stem cells and late metastases.Frontiers in oncology · 2024Review
- Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms.Journal of clinical medicine · 2023Review
- Recurrence-Free Survival in Early and Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung after Complete Tumor Resection.Journal of personalized medicine · 2023Article
- Bone Loss in Patients with Pancreatic Neuroendocrine Tumors.Journal of clinical medicine · 2022Article
- Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.Endocrine · 2022Article
- The Potential Prognostic Value of Dual-Imaging PET Parameters Based onMolecular imaging · 2022Article
- Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021Review
- Targeting Bone Metastasis in Cancers.Cancers · 2021Article
- Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone represents a common site of metastases for several solid tumors. However, the ability of neuroendocrine neoplasms (NENs) to localize to bone has always been considered a rare and late event. Thanks to the improvement of therapeutic options, which results in longer survival, and of imaging techniques, particularly after the introduction of positron emission tomography (PET) with gallium peptides, the diagnosis of bone metastases (BMs) in NENs is increasing. The onset of BMs can be associated with severe skeletal complications that impair the patient's quality of life. Moreover, BMs negatively affect the prognosis of NEN patients, bringing out the lack of curative treatment options for advanced NENs. The current knowledge on BMs in gastro-entero-pancreatic (GEP) and bronchopulmonary (BP) NENs is still scant and is derived from a few retrospective studies and case reports. This review aims to perform a critical analysis of the evidence regarding the role of BMs in GEP- and BP-NENs, focusing on the molecular mechanisms underlining the development of BMs, as well as clinical presentation, diagnosis, and treatment of BMs, in an attempt to provide suggestions that can be used in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.